Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
1.480
-0.020 (-1.33%)
At close: Nov 20, 2026, 4:00 PM EST
1.530
+0.050 (3.38%)
After-hours: Nov 20, 2026, 7:34 PM EST
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or 12.50% compared to the previous year. That makes Lipocine the 39,426th largest employer in the world and 5,761st in the United States.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$267,497
Profits / Employee
-$666,483
Market Cap
16.39M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Seres Therapeutics | 66 |
| BeyondSpring | 44 |
| Atossa Therapeutics | 16 |
| Context Therapeutics | 15 |
| NewcelX | 12 |
| Cocrystal Pharma | 10 |
| Quoin Pharmaceuticals | 6 |
LPCN News
- 10 days ago - Lipocine doses first patient in Phase 3 study evaluating LPCN 1154 - TheFly
- 10 days ago - Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PRNewsWire
- 15 days ago - Lipocine Announces Financial Results for the Third Quarter of 2026 - PRNewsWire
- 15 days ago - Lipocine Quarterly report: Q3 2026 - Filings
- 15 days ago - Lipocine Earnings release: Q3 2026 - Filings
- 4 weeks ago - Lipocine Slides: Corporate presentation - Filings
- 6 weeks ago - 3 Penny Stocks to Watch Today, October 8 - TipRanks
- 6 weeks ago - Lipocine announces Health Canada approved TLANDO capsules - TheFly